DDX53 and neoplasm: The HER2-TG BALB/c mice, s.c. implanted with CT26-HER2 tumors, received three i.t. inoculations of R-337 and simultaneous i.p. treatment with anti-CTLA-4, as detailed in Figure 5A. Figure 5C shows that the growth of CT26-HER2 tumor was partially inhibited by anti-CTLA-4 monotherapy (CR in 57% of the mice).